Dr. Michael Venincasa, MD

Dr. Venincasa practices at Surgeon's Cosmetic Center & Medspa LLC in Miami, Florida.

Dr. Venincasa's NPI, 1811456833, was assigned on March 19, 2019. Dr. Venincasa graduated from University of Miami Leonard M. Miller School of Medicine in 2019. Dr. Venincasa holds Florida license ME160813.

Dr. Venincasa's primary practice is Surgeon's Cosmetic Center & Medspa LLC, at 8585 Sunset Dr, Miami, FL 33143 in Miami-Dade County. The practice phone is (305) 274-3393.

Dr. Venincasa's primary practice is Surgeon's Cosmetic Center & Medspa LLC in Miami, Florida. Dmand AI also links Dr. Venincasa to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Venincasa practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Venincasa's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Venincasa is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Venincasa is licensed in Florida.

Dmand AI lists cataract, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Venincasa treats.

CMS data shows 305 Medicare services from Dr. Venincasa across 10 procedure codes in 2024, for 143 Medicare patients. Medicare paid $17,055 for them. Every service was in an office.

CMS counts 143 Medicare patients who saw Dr. Venincasa in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.05, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Venincasa's median patient age at 61, with 58% women.

In 2024, Dr. Venincasa wrote 372 Medicare Part D claims for 151 patients. 45% of them were for generic drugs. CMS names the drug for 291 of them, across 9 drugs with 11 or more claims each, at $68,374 in total drug cost. In 2023, CMS named 576 claims across 10 drugs.

Dr. Venincasa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 46 procedures of cataract surgery by Dr. Venincasa, more than 62% of the clinicians it reports for that procedure.

Dmand AI links 26 papers to Dr. Venincasa, published from 2012 to 2023. 2020 was the busiest year, with 6. The most frequent topics are Ophthalmology, Educational Measurement and Internship and Residency. Dr. Venincasa has published most often in Clin Ophthalmol. Dr. Venincasa's most frequent co-authors are Jayanth Srinivasan-Kasi Sridhar, MD, Hasenin Raid Hashim Al-Khersan, MD and Ajay Eapen Kuriyan, MD.

CMS Open Payments shows 220 general payments to Dr. Venincasa from 23 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 97% of the total. Alcon Laboratories Inc paid the most, $2,543.

Dr. Venincasa graduated from University of Miami Leonard M. Miller School of Medicine in 2019.

Dr. Venincasa is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.